Comparison · NCT02184195-sae
Olaparib 300 mg Twice Daily (bd) vs Placebo: serious adverse events
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Olaparib 300 mg Twice Daily (bd) vs Placebo: serious adverse events. Trial comparisons, record NCT02184195-sae. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT02184195-sae
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.311 | 0.225 | 0.413 | wilson | |
| Risk in group 2 | 0.164 | 0.0916 | 0.276 | wilson | |
| Risk difference, group 1 minus group 2 | 0.147 | 0.00566 | 0.272 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 1.9 | 0.996 | 3.62 | log | |
| Odds ratio, group 1 over group 2 | 2.3 | 1.02 | 5.19 | log | |
| Number needed to harm, for one more participant with a serious adverse event on Olaparib 300 mg Twice Daily (bd) than on Placebo | 6.79 | 3.68 | 177 | from the risk difference interval |
Source ClinicalTrials.gov
Groups2
Group 2 names the comparator: placebo.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Olaparib 300 mg Twice Daily (bd) | Randomised participants received orally 300 mg bd which were made up of 2 x 150 mg tablets bd with 100 mg tablets used to manage dose reductions. | 28 | 90 | EG000 |
| Group 2 | Placebo | Randomised participants received placebo tablets orally 300 mg bd which were made up of 2 x 150 mg tablets bd with 100 mg tablets used to manage dose reductions. | 10 | 61 | EG001 |
Source ClinicalTrials.gov
Harm
- What it counts
- Total, serious adverse events
- Time frame
- From informed consent until 30 days after last dose + subsequent treatment-related events reported (maximum up to 4 years).
Source ClinicalTrials.gov
Trial
- Title
- Olaparib in gBRCA Mutated Pancreatic Cancer Whose Disease Has Not Progressed on First Line Platinum-Based Chemotherapy
- NCT number
- NCT02184195
- Phases
- PHASE3
- Conditions
- Germline BRCA1/2 Mutations and, Metastatic Adenocarcinoma of the Pancreas
- Interventions
- Olaparib, Olaparib, Placebo, Placebo
- Lead sponsor
- AstraZeneca
- Results first posted
- 2020-01-27
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT02184195?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT02184195-sae